t(1;14)(q21;q32) FCGR2B/IGH by Boyer, J









Atlas Genet Cytogenet Oncol Haematol. 2005; 9(2)  
 
155 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
t(1;14)(q21;q32) FCGR2B/IGH 
Jacques Boyer 
Laboratoire d’hématologie, CH du MANS, France (JB) 
Published in Atlas Database: February 2005 
Online updated version: http://AtlasGeneticsOncology.org/Anomalies/t0114q21q32ID1341.html 
DOI: 10.4267/2042/38191 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2005 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Clinics and pathology 
Disease 
Follicular lymphoma in one CD10+ case, but without a 
t(14;18)(q32;q21), bcl2 negative, and with a 
t(1;14)(q21;q32); follicular lymphoma with FCGR2B 
rearrangement and dup(1)(q21q25)in another case . 
Epidemiology 
These two cases with FCGR2B rearrangement were 
found among a panel of 76 non Hodgkin's lymphomas. 
Prognosis 
May be associated with tumor progression. 
Cytogenetics 
Cytogenetics morphological 
One case with 46, XX, t(1;14)(q21;q32), 
t(8;9)(q24;q13); progression to a diffuse large cells 
lymphoma with a complexe caryotype. An another case 
with FCGR2B rearrangement in a follicular lymphoma: 
the karyotype was complexe with dup(1)(q21q25), 
t(14;18)(q32;q21). 











The translocation juxtapose the 5' switch region og 
IGHG2 to a region upstream of FCGR2B in the der(1) 
chromosome.FCGR2B is deregulated by this 




No fusion protein. 
Oncogenesis 
It is possible that alteration in the b2/b1 mRNA 
isoforms ratio in B-cells may promote B cell survival. 
This anomaly is bcl2 deregulation-independant because 
FCGR2B has been shown to be a tumor-enhancing 
factor in non lymphoid cells in murine in vivo and in 
vitro models. Deregulation of FCGR2B expression can
be considered as a second event which may impart 
additional growth advantage to the bcl2 deregulated B-
cells. 
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